Neurodevelopmental Diseases Program

About DiamiR

DiamiR is a private, pre-revenue diagnostics company pioneering a platform based on brain-enriched microRNA biomarkers detectable in blood plasma. Its lead program, CogniMIR™, targets the early detection of mild cognitive impairment and Alzheimer's disease, with additional programs in neurodevelopmental disorders and healthy aging. The company aims to address critical unmet needs in screening, differential diagnosis, and therapy monitoring through collaborations with academia and industry, supported by a growing intellectual property portfolio.

Therapeutic Areas